CALGARY, July 11, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW), at the request of IIROC on behalf of the Canadian Securities Exchange, announces that it is not aware of any material facts or changes in respect of the business of the Company which would result in a significant change in the trading price and volume of the common shares of the Company.
About Willow Biosciences Inc.
Headquartered in Calgary, Canada, Willow and its team of scientists are leaders in the field of biosynthetic production of high value plant-derived compounds. Willow has applied its integrated suite of technologies to develop manufacturing processes for numerous active pharmaceutical ingredients with various therapeutic benefits, including cancer treatment, pain management, and CNS disorders. In the cannabinoid field, Willow owns proprietary yeast-based lab strains that produce CBD, tetrahydrocannabinol (THC), and cannabigerol (CBG), as well as certain minor and novel cannabinoids.
Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Willow Biosciences Inc.
For further information: Trevor Peters, President and Chief Executive Officer, T: (403) 669-4848, E: email@example.com; Troy Talkkari, CFA, Vice President, Corporate Development, T: (403) 618-1117, E: firstname.lastname@example.org; 202, 1201 - 5th Street SW, Calgary, AB T2R 0Y6